Cargando…
Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment
The existing clinical protocols of hepatoma treatment require improvement of drug efficacy that can be achieved by harnessing nanomedicine. Porphyrin-based, paddle-wheel framework (PPF) structures were obtained and tested as dual-kinetic Sorafenib (SOR) nanocarriers against hepatoma. We experimental...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536990/ https://www.ncbi.nlm.nih.gov/pubmed/34681820 http://dx.doi.org/10.3390/ijms222011161 |
_version_ | 1784588141208797184 |
---|---|
author | Bieniek, Adam Wiśniewski, Marek Czarnecka, Joanna Wierzbicki, Jędrzej Ziętek, Marcin Nowacki, Maciej Grzanka, Dariusz Kloskowski, Tomasz Roszek, Katarzyna |
author_facet | Bieniek, Adam Wiśniewski, Marek Czarnecka, Joanna Wierzbicki, Jędrzej Ziętek, Marcin Nowacki, Maciej Grzanka, Dariusz Kloskowski, Tomasz Roszek, Katarzyna |
author_sort | Bieniek, Adam |
collection | PubMed |
description | The existing clinical protocols of hepatoma treatment require improvement of drug efficacy that can be achieved by harnessing nanomedicine. Porphyrin-based, paddle-wheel framework (PPF) structures were obtained and tested as dual-kinetic Sorafenib (SOR) nanocarriers against hepatoma. We experimentally proved that sloughing of PPF structures combined with gradual dissolving are effective mechanisms for releasing the drug from the nanocarrier. By controlling the PPF degradation and size of adsorbed SOR deposits, we were able to augment SOR anticancer effects, both in vitro and in vivo, due to the dual kinetic behavior of SOR@PPF. Obtained drug delivery systems with slow and fast release of SOR influenced effectively, although in a different way, the cancer cells proliferation (reflected with EC50 and ERK 1/2 phosphorylation level). The in vivo studies proved that fast-released SOR@PPF reduces the tumor size considerably, while the slow-released SOR@PPF much better prevents from lymph nodes involvement and distant metastases. |
format | Online Article Text |
id | pubmed-8536990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85369902021-10-24 Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment Bieniek, Adam Wiśniewski, Marek Czarnecka, Joanna Wierzbicki, Jędrzej Ziętek, Marcin Nowacki, Maciej Grzanka, Dariusz Kloskowski, Tomasz Roszek, Katarzyna Int J Mol Sci Article The existing clinical protocols of hepatoma treatment require improvement of drug efficacy that can be achieved by harnessing nanomedicine. Porphyrin-based, paddle-wheel framework (PPF) structures were obtained and tested as dual-kinetic Sorafenib (SOR) nanocarriers against hepatoma. We experimentally proved that sloughing of PPF structures combined with gradual dissolving are effective mechanisms for releasing the drug from the nanocarrier. By controlling the PPF degradation and size of adsorbed SOR deposits, we were able to augment SOR anticancer effects, both in vitro and in vivo, due to the dual kinetic behavior of SOR@PPF. Obtained drug delivery systems with slow and fast release of SOR influenced effectively, although in a different way, the cancer cells proliferation (reflected with EC50 and ERK 1/2 phosphorylation level). The in vivo studies proved that fast-released SOR@PPF reduces the tumor size considerably, while the slow-released SOR@PPF much better prevents from lymph nodes involvement and distant metastases. MDPI 2021-10-16 /pmc/articles/PMC8536990/ /pubmed/34681820 http://dx.doi.org/10.3390/ijms222011161 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bieniek, Adam Wiśniewski, Marek Czarnecka, Joanna Wierzbicki, Jędrzej Ziętek, Marcin Nowacki, Maciej Grzanka, Dariusz Kloskowski, Tomasz Roszek, Katarzyna Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment |
title | Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment |
title_full | Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment |
title_fullStr | Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment |
title_full_unstemmed | Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment |
title_short | Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment |
title_sort | porphyrin based 2d-mof structures as dual-kinetic sorafenib nanocarriers for hepatoma treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536990/ https://www.ncbi.nlm.nih.gov/pubmed/34681820 http://dx.doi.org/10.3390/ijms222011161 |
work_keys_str_mv | AT bieniekadam porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment AT wisniewskimarek porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment AT czarneckajoanna porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment AT wierzbickijedrzej porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment AT zietekmarcin porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment AT nowackimaciej porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment AT grzankadariusz porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment AT kloskowskitomasz porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment AT roszekkatarzyna porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment |